Mitobronitol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H100626

CAS#: 488-41-5

Description: Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is classified as an alkylating agent. (Source: http://en.wikipedia.org/wiki/Mitobronitol)

Chemical Structure

img
Mitobronitol
CAS# 488-41-5
Instruction

Theoretical Analysis

Hodoodo Cat#: H100626
Name: Mitobronitol
CAS#: 488-41-5
Chemical Formula: C6H12Br2O4
Exact Mass: 305.91
Molecular Weight: 307.960
Elemental Analysis: C, 23.40; H, 3.93; Br, 51.89; O, 20.78

Price and Availability

Size Price Availability Quantity
250mg USD 650
1g USD 795
Bulk inquiry

Synonym: 16dibromo16dideoxyDMannitol

IUPAC/Chemical Name: (2S,3S,4S,5S)-1,6-dibromohexane-2,3,4,5-tetraol

InChi Key: VFKZTMPDYBFSTM-KVTDHHQDSA-N

InChi Code: InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4-,5-,6-/m1/s1

SMILES Code: O[C@@H]([C@@H](O)[C@H](O)[C@H](O)CBr)CBr

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is classified as an alkylating agent. Pharmacological action: antineoplastic agent, alkylating.       

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 307.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tanaka Y, Nagai Y, Mori M, Fujita H, Togami K, Kurata M, Matsushita A, Maeda A, Nagai K, Tanaka K, Takahashi T. Multiple granulocytic sarcomas in essential thrombocythemia. Int J Hematol. 2006 Dec;84(5):413-6. PubMed PMID: 17189221.

2: Barta A, Dénes R, Masszi T, Reményi P, Bátai A, Torbágyi E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Avalos M, Pálóczi K, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Kelemen E, Petrányi G. Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol. 2001;105(2):64-70. PubMed PMID: 11408706.

3: Windrum P, Hull DR, Morris TC. Herb-drug interactions. Lancet. 2000 Mar 18;355(9208):1019-20. PubMed PMID: 10768466.

4: Barta A, Bátai A, Kelemen E, Lengyel L, Reményi P, Sipos A, Torbágyi E, Avalos M, Fekete E, Földi J, Páldi-Haris P, Tamáska J, Gyódi E, Rajczy K, Hoffer I, Jakab J, Petrányi GG, Pálóczi K. Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. Hum Immunol. 2000 Feb;61(2):101-10. Review. PubMed PMID: 10717801.

5: Masszi T, Reményi P, Kriván G, Goda V, Réti M. Allogeneic bone marrow transplantation for acute leukemia in adults. Bone Marrow Transplant. 1998 Dec;22 Suppl 4:S77-9. PubMed PMID: 9916643.

6: Barta A, Batai A, Torbagyi E, Sipos A, Lengyel L, Petranyi GG, Paloczi K, Kelemen E. Haemopoietic cell transplantation activity and results: a single institution experience. Bone Marrow Transplant. 1998 Dec;22 Suppl 4:S60-2. PubMed PMID: 9916638.

7: Kelemen E, Dénes R, Barta A, Masszi T, Reményi P, Pálóczi K, Bátai A, Torbágyo E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Manuel A, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Petrányi G. [A new radiation-free conditioning in bone marrow transplantation and dibromo-mannitol therapy in chronic myeloid leukemia]. Orv Hetil. 1998 Aug 23;139(34):2003-1; discussion 2011-2. Review. Hungarian. PubMed PMID: 9745304.

8: Kelemen E, Masszi T, Reményi P, Barta A, Pálóczi K. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination. Bone Marrow Transplant. 1998 Apr;21(8):747-9. PubMed PMID: 9603396.

9: Szebeni J, Barna K, Uher F, Milosevits J, Pálóczi K, Gaál D, Petrányi GG, Kelemen E. Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning. Leukemia. 1997 Oct;11(10):1769-74. PubMed PMID: 9324299.

10: Tsuji T. Erythemas associated with essential thrombocythemia. J Dermatol. 1995 Oct;22(10):788-94. PubMed PMID: 8586763.